ABSTRACT
Objective: to evaluate the efficacy of the combination therapy of mometasone and pimecrolimus in the treatment of vitiligo in children
Methods: in this double-blind randomized controlled trial, 50 patients were enrolled. Based on the planned treatment protocol, three lesions with approximately identical size at similar anatomic sites were selected in each patient. Lesions were divided to three groups: pimecrolimus cream 1 % [twice a day], mometasone furoate ointment 0.1 % [every night], and combined therapy group [pimecrolimus twice a day on weekdays and mometasone every night on weekends], all being applied for three months. They were followed up for three months
Results: forty patients [with 46% of cases being male] with a mean age of 10.6 years completed the study. There was no significant difference in response rate between three groups at the end of the treatment
Conclusion: our study results did not demonstrate significant difference in the response rate and adverse effects between combined treatment group and either alone